Immuno-metabolic diseases emerge in clusters since a state of chronic systemic inflammation associated to metabolic dysfunction disrupts homeostasis in multiple organs such as adipose tissue and brain (Hotamisligil, 2017) . The association between obesity and depression is well established (Lasselin and Capuron, 2014) , although the underlying pathophysiological mechanisms remain unrevealed. Lamers et al. (2018) found increased appetite as the core symptom driving the associations between depression and both metabolic and inflammatory markers highlighting a specific biological type of depression. The novelty of such findings resides in the mechanisms regulating appetite such as dopaminergic pathways being also involved in immunomodulation and inflammation. Systemic inflammation is a stronger contributor of obesity-related depressive symptoms than metabolic dysfunction per se (Delgado et al., 2018) . Major depressive disorder patients, during a depressive episode, have a subclinical inflammation and reduced response to lipopolysaccharide in monocytes (Zhang et al., 2018) . Moreover, higher leptin was associated with hyperphagia, independently from weight (Milaneschi et al., 2017) . We found that plasma levels of leptin, very-low-density lipoprotein-cholesterol and CD14 expression in monocyte subsets are predictors of subclinical inflammatory obesity (Leite et al., 2017a) , which can constitute an important tool for early therapeutic interventions in obesity-related comorbidities, namely depression. Dopaminergic pathways have a major role in appetite regulation and as immunoregulators in inflammation. Immune cells, neurons and adipocytes share common signalling pathways mediated by catecholamines (CA), and dopamine (DA) plays a prominent and so far, possibly underestimated role (Flierl et al., 2008; Borcherding et al., 2011; Pinoli et al., 2017) . DA regulates behaviour, reward, movement, endocrine, cardiovascular, renal and gastrointestinal functions, but it is also a crucial transmitter in the neuroimmune network, contributing to the nervous-immune systems interplay as well as in the communication among immune cells (Pinoli et al., 2017) . We showed that central obesity is associated with a distinct pattern of CA receptors in circulating immune cells and that β 2 -adrenoceptors (AR) and dopaminergic receptors (DR)D 2 might be protective towards visceral obesity (Leite et al., 2016 (Leite et al., , 2017b . β 2 -AR and DRD 2 transcripts were associated with lower inflammatory pattern of monocytes and with a better metabolic profile, suggesting an immunomodulatory role for CA in obesity-associated inflammation.
DA exerts its effects through the interaction with five different DR (D 1−5 ). Human monocytes express all DR and evidence suggests that DA inhibit monocyte NLRP3 inflammasome thus resulting in the reduction of the inflammatory processes (Pinoli et al., 2017 . Expansion of the intermediate monocyte subset has been described in chronic inflammatory diseases (Wong et al., 2012) , while the contribution of non-classical monocyte subset in inflammation remains unclear.
We studied DR expression in human monocyte subsets and the effect of DA on phosphorylation of monocyte signal transducer and activator of transcription 3 (STAT3), a crucial step in the production of pro-inflammatory cytokines in obesity and interacts with the doublestranded RNA-sensing kinase PKR, a critical mediator of inflammasome activity and metabolic regulation (Hotamisligil, 2017) . Our results show that all five DR are expressed by circulating monocytes, however DR+ cells are on average only 16-33% of classical and intermediate monocytes but about 89-96% of non-classical monocytes, and incubation of whole blood with DA reduced IL-6-induced phosphorylation of STAT3 in CD14+ monocytes (Fig. 1) .
Preferential DR expression on non-classical monocytes in comparison with classical and intermediate monocyte subsets suggests that DA anti-inflammatory effects involve mainly non-classical monocytes. Our findings in human monocytes of reduction of IL-6-induced STAT3 phosphorylation by DA infers an immunomodulatory role for this CA given STAT3 function in the production of pro-inflammatory cytokines and its interaction with PKR mediating metabolic signals and inflammasome activity.
DA and dopaminergic agonists interfere with tumour necrosis factor-α and nitric oxide production in mouse monocytes and DA modulate the expression of surface markers, such as the Fc-γ receptor, important for host defence (Pinoli et al., 2017) . This suggests that dopaminergic pathways in human monocytes may counteract the effects of proinflammatory stimuli, acting on the non-classical subset and to a minor extent in the intermediate subset, the main responding subset of monocytes to standardized low-grade inflammation (Thaler et al., 2016) .
Macrophages convey information to the nervous system regulating behaviour, metabolism and inflammation through direct access to CA produced by the sympathetic nerve (Camell et al., 2017) . However, monocytes/macrophages themselves produce CA (Marino and Cosentino, 2013; Pinoli et al., 2017) . CA, particularly DA, are key signalling molecules connecting monocytes/macrophages, adipocytes and sympathetic nerve terminals thus regulating immuno-metabolic disease clusters including depression. Dopaminergic pathways might thus allow simultaneously targeting adiposity, inflammation and the immuno-metabolic depression.
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